CHMP Adopts Positive Opinion for the Expansion of the Translarna™ (ataluren) Label to Include Patients as Young as 2 Years of Age

- European Commission ratification anticipated in coming months – - Approval of the Translarna annual re-assessment also recommended by CHMP - SOUTH PLAINFIELD, N.J., June 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for...

from PR Newswire: //https://ift.tt/2J9mQAy